Transcatheter Aortic Valve Replacement (TAVR) Clinical Trials

Clinical trials related to Transcatheter Aortic Valve Replacement (TAVR) Procedure

A Randomized Controlled Trial of Anti-Inflammatory Therapy to Reduce Transcatheter Heart Valve Thrombosis After Transfemoral Transcatheter Aortic Valve Replacement

Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This prospective, randomized, open-label study aims to evaluate the efficacy and safety of low-dose colchicine (0.5 mg daily) in reducing transcatheter heart valve (THV) thrombosis in patients after TAVR. Participants will be randomly assigned to either receive colchicine plus standard care or standard care alone for 12 months. The primary goal is to compare the rate of valve thrombosis between the two groups using 4D-CT imaging at one year. Additionally, the study will evaluate the treatment's impact on clinical outcomes and its overall safety profile.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Maximum Age: 85
Healthy Volunteers: f
View:

• Patients with aortic stenosis aged 60-85 years.

• Successful transfemoral TAVR (per VARC-3 criteria).

• Voluntary participation with signed Informed Consent Form.

Locations
Other Locations
China
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING
Beijing
Contact Information
Primary
Yunqing Ye, MD, PhD
judia8510@163.com
8613699282532
Time Frame
Start Date: 2026-03-12
Estimated Completion Date: 2028-06
Participants
Target number of participants: 116
Treatments
Experimental: Colchicine Group
0.5 mg once daily (QD) orally for 12 months, starting after successful TAVR and stabilization before discharge, on top of standard care.
Active_comparator: Conventional Treatment
Standard pharmacological management and long-term postoperative care according to current clinical guidelines and expert consensus for TAVR patients, without the use of colchicine.
Sponsors
Collaborators: Chinese Academy of Medical Sciences
Leads: China National Center for Cardiovascular Diseases

This content was sourced from clinicaltrials.gov